0.7964
price up icon9.92%   0.0719
pre-market  Pre-market:  .80   0.0036   +0.45%
loading
Nektar Therapeutics stock is traded at $0.7964, with a volume of 2.37M. It is up +9.92% in the last 24 hours and up +5.90% over the past month. Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$0.7245
Open:
$0.7399
24h Volume:
2.37M
Relative Volume:
1.18
Market Cap:
$148.21M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-0.5455
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
+21.76%
1M Performance:
+5.90%
6M Performance:
-32.51%
1Y Performance:
-37.29%
1-Day Range:
Value
$0.7003
$0.8198
1-Week Range:
Value
$0.6319
$0.8198
52-Week Range:
Value
$0.432
$1.5195

Nektar Therapeutics Stock (NKTR) Company Profile

Name
Name
Nektar Therapeutics
Name
Phone
(415) 482-5300
Name
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
Employee
61
Name
Twitter
@nektarnews
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
NKTR's Discussions on Twitter

Compare NKTR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTR
Nektar Therapeutics
0.7964 125.53M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-11-25 Upgrade Jefferies Hold → Buy
Mar-14-25 Upgrade Oppenheimer Perform → Outperform
Jan-08-25 Initiated B. Riley Securities Buy
Dec-10-24 Initiated H.C. Wainwright Buy
Nov-04-24 Initiated Piper Sandler Overweight
Sep-30-24 Resumed BTIG Research Buy
Jun-28-24 Initiated Rodman & Renshaw Buy
Nov-20-23 Resumed JP Morgan Underweight
Nov-09-23 Upgrade TD Cowen Market Perform → Outperform
May-10-23 Upgrade Jefferies Underperform → Hold
Feb-24-23 Downgrade Jefferies Hold → Underperform
Aug-08-22 Downgrade JP Morgan Neutral → Underweight
May-31-22 Resumed Jefferies Hold
Apr-18-22 Downgrade Goldman Neutral → Sell
Mar-15-22 Downgrade Cowen Outperform → Market Perform
Mar-15-22 Downgrade Mizuho Buy → Neutral
Mar-14-22 Downgrade BTIG Research Buy → Neutral
Mar-14-22 Downgrade BofA Securities Neutral → Underperform
Mar-14-22 Downgrade Stifel Buy → Hold
Mar-14-22 Downgrade William Blair Outperform → Mkt Perform
Mar-09-22 Upgrade Oppenheimer Perform → Outperform
Nov-08-21 Upgrade The Benchmark Company Hold → Buy
Sep-10-21 Initiated BofA Securities Neutral
Jun-28-21 Upgrade Stifel Hold → Buy
May-18-21 Resumed Goldman Neutral
Feb-22-21 Downgrade The Benchmark Company Buy → Hold
Jan-06-21 Initiated Stifel Hold
Sep-14-20 Initiated JP Morgan Neutral
Jun-10-20 Downgrade CFRA Hold → Sell
May-12-20 Reiterated H.C. Wainwright Neutral
Apr-22-20 Initiated The Benchmark Company Buy
Mar-30-20 Upgrade Goldman Sell → Neutral
Mar-04-20 Initiated Barclays Overweight
Feb-03-20 Upgrade Mizuho Neutral → Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-08-19 Downgrade Goldman Buy → Sell
Aug-09-19 Downgrade JP Morgan Overweight → Neutral
Aug-09-19 Downgrade Jefferies Buy → Hold
Aug-09-19 Downgrade Mizuho Buy → Neutral
Mar-15-19 Initiated SVB Leerink Mkt Perform
Dec-13-18 Initiated Goldman Buy
Jun-11-18 Downgrade H.C. Wainwright Buy → Neutral
Jun-04-18 Reiterated H.C. Wainwright Buy
Apr-20-18 Initiated Seaport Global Securities Buy
Apr-13-18 Resumed Piper Jaffray Overweight
Apr-06-18 Reiterated Mizuho Buy
Apr-02-18 Resumed H.C. Wainwright Buy
View All

Nektar Therapeutics Stock (NKTR) Latest News

pulisher
May 30, 2025

Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 30, 2025
pulisher
May 29, 2025

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025
pulisher
May 28, 2025

Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 28, 2025
pulisher
May 28, 2025

Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks

May 28, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World

May 22, 2025
pulisher
May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025
pulisher
May 16, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

May 16, 2025
pulisher
May 16, 2025

Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World

May 16, 2025
pulisher
May 16, 2025

What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World

May 16, 2025
pulisher
May 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 15, 2025
pulisher
May 15, 2025

Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World

May 15, 2025
pulisher
May 14, 2025

GSK’s liver asset play grows group of $1B upfront deals - biocentury.com

May 14, 2025
pulisher
May 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

May 13, 2025
pulisher
May 13, 2025

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World

May 13, 2025
pulisher
May 12, 2025

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 12, 2025
pulisher
May 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 12, 2025
pulisher
May 12, 2025

Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com

May 12, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st

May 09, 2025
pulisher
May 09, 2025

NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView

May 09, 2025
pulisher
May 09, 2025

BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com

May 09, 2025
pulisher
May 09, 2025

Nektar: Q1 Earnings Snapshot - The Washington Post

May 09, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses E - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timel - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq

May 08, 2025

Nektar Therapeutics Stock (NKTR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Cap:     |  Volume (24h):